TipRanks
Advertisement
Advertisement

ABCL Stock Latest News

AbCellera to present Phase 2 Data for ABCL635 at IMS Congress on Menopause
The FlyAbCellera to present Phase 2 Data for ABCL635 at IMS Congress on Menopause
36m ago
ABCL
AbCellera Biologics call volume above normal and directionally bullish
PremiumThe Fly
AbCellera Biologics call volume above normal and directionally bullish
1d ago
ABCL
AbCellera rises 17.0%
PremiumThe Fly
AbCellera rises 17.0%
22d ago
ABCL
AbCellera rises 10.7%
PremiumThe Fly
AbCellera rises 10.7%
22d ago
ABCL
AbCellera Biologics call volume above normal and directionally bullish
PremiumThe Fly
AbCellera Biologics call volume above normal and directionally bullish
28d ago
ABCL
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
29d ago
YSS
ABCL
AbCellera 17.4M share Secondary priced at $9.75
Premium
The Fly
AbCellera 17.4M share Secondary priced at $9.75
1M ago
ABCL
AbCellera Biologics call volume above normal and directionally bullish
Premium
The Fly
AbCellera Biologics call volume above normal and directionally bullish
1M ago
ABCL
AbCellera Biologics Announces Oversubscribed $200 Million Offering
PremiumCompany Announcements
AbCellera Biologics Announces Oversubscribed $200 Million Offering
1M ago
8K
ABCL
AbCellera announces $200M common stock, warrants offering
PremiumThe Fly
AbCellera announces $200M common stock, warrants offering
1M ago
ABCL
AbCellera price target raised to $30 from $12 at Truist
PremiumThe Fly
AbCellera price target raised to $30 from $12 at Truist
1M ago
ABCL
AbCellera Price Target Raised to $15 on Best-in-Class ABCL635 Phase 2 Data and Strategic Pipeline Momentum
PremiumRatings
AbCellera Price Target Raised to $15 on Best-in-Class ABCL635 Phase 2 Data and Strategic Pipeline Momentum
1M ago
ABCL
AbCellera price target raised to $25 from $13 at JonesResearch
PremiumThe FlyAbCellera price target raised to $25 from $13 at JonesResearch
1M ago
ABCL
AbCellera announces Phase 1/2 trial of ABCL635 met primary efficacy endpoints
Premium
The Fly
AbCellera announces Phase 1/2 trial of ABCL635 met primary efficacy endpoints
1M ago
ABCL
AbCellera Earnings Call Balances Cash Strength With Risk
Premium
Company Announcements
AbCellera Earnings Call Balances Cash Strength With Risk
1M ago
ABCL
AbCellera to Report Phase 2 Menopause Therapy Data
PremiumCompany Announcements
AbCellera to Report Phase 2 Menopause Therapy Data
1M ago
8K
ABCL
AbCellera price target raised to $9 from $8 at Stifel
PremiumThe Fly
AbCellera price target raised to $9 from $8 at Stifel
1M ago
ABCL
AbCellera price target raised to $12 from $11 at Cantor Fitzgerald
PremiumThe Fly
AbCellera price target raised to $12 from $11 at Cantor Fitzgerald
1M ago
ABCL
Analyst Brendan Smith Reiterates Buy on AbCellera, Citing Strong Liquidity and Upcoming Phase 2 Data for ABCL635 in Hot-Flash Market
PremiumRatings
Analyst Brendan Smith Reiterates Buy on AbCellera, Citing Strong Liquidity and Upcoming Phase 2 Data for ABCL635 in Hot-Flash Market
1M ago
ABCL
AbCellera reports Q2 EPS (18c), consensus (17c)
PremiumThe FlyAbCellera reports Q2 EPS (18c), consensus (17c)
1M ago
ABCL
AbCellera and Vertex launch autoimmune T-cell engager partnership
Premium
Company Announcements
AbCellera and Vertex launch autoimmune T-cell engager partnership
2M ago
8K
ABCL
AbCellera announces collaboration with Vertex Pharmaceuticals
Premium
The Fly
AbCellera announces collaboration with Vertex Pharmaceuticals
2M ago
ABCL
VRTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >